The extended half-life Factor VIII concentrate currently used in Ireland is Elocta. However, in the coming months, this will be changed to a new enhanced extended half-life Factor VIII from the same company. This new product is called Altuvoct and was licensed by the European Medicines Agency in recent months. Altuvoct will be used by those currently on prophylaxis with Elocta or by those who may wish to consider a switch from Hemlibra. For those on Hemlibra, treatment for bleeding episodes will continue to be provided by Elocta as there is currently no suitable laboratory assay to measure Altuvoct in those currently treated with Hemlibra. Individual discussions will, of course, take place between your haemophilia treatment centre and you prior to the switch.
We have arranged a virtual meeting on the Zoom platform which will take place on Thursday 14th November at 7pm to discuss this new treatment with members. Professor Niamh O’Connell and Dr. Beatrice Nolan will attend this meeting.
Please see below the log in details for this meeting.
Join Zoom Meeting
https://us02web.zoom.us/j/6901047198?pwd=anZqckEwK3d0bHExOUM4ZlNUQkxqdz09&omn=84264012414
Meeting ID: 690 104 7198
Passcode: 1968
We are looking forward to seeing you there!